Gefitinib
- Generic Name
- Gefitinib
- Brand Names
- Iressa, Gefitinib Mylan
- Drug Type
- Small Molecule
- Chemical Formula
- C22H24ClFN4O3
- CAS Number
- 184475-35-2
- Unique Ingredient Identifier
- S65743JHBS
- Background
Gefitinib (originally coded ZD1839) is a drug used in the treatment of certain types of cancer. Acting in a similar manner to erlotinib (marketed as Tarceva), gefitinib selectively targets the mutant proteins in malignant cells. It is marketed by AstraZeneca under the trade name Iressa.
- Indication
For the continued treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of either platinum-based or docetaxel chemotherapies.
- Associated Conditions
- Metastatic Non-Small Cell Lung Cancer
- Associated Therapies
- -
ZD1839 (Iressa™) and Concurrent Chemo-Radiation in Patients With Locally Advanced Non Small Cell Lung Cancer
- Conditions
- First Posted Date
- 2005-11-15
- Last Posted Date
- 2007-12-19
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 44
- Registration Number
- NCT00252798
- Locations
- 🇦🇺
Research Site, East Melbourne, Victoria, Australia
ZD1839 (Iressa™) In Combination With Docetaxel As First-Line Treatment In Patients With Metastatic Breast Cancer
- Conditions
- First Posted Date
- 2005-11-02
- Last Posted Date
- 2009-04-23
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 77
- Registration Number
- NCT00247481
- Locations
- 🇫🇷
Research Site, Villejuif Cedex, France
Phase II Gemcitabine + Cisplatin +/- Iressa Bladder CCT
- Conditions
- Interventions
- First Posted Date
- 2005-11-01
- Last Posted Date
- 2008-10-15
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 125
- Registration Number
- NCT00246974
- Locations
- 🇩🇪
Research Site, Ulm, Germany
Iressa vs Best Supportive Care - 2nd/3rd Line Survival Study
- Conditions
- First Posted Date
- 2005-10-21
- Last Posted Date
- 2009-04-23
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1692
- Registration Number
- NCT00242801
- Locations
- 🇻🇪
Research Site, Various Cities, Venezuela
Gefitinib in the Treatment of the First Relapse of Prostate Cancer Beyond Prostatectomy or Radiotherapy
- Conditions
- First Posted Date
- 2005-10-19
- Last Posted Date
- 2009-04-23
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 30
- Registration Number
- NCT00241475
- Locations
- 🇫🇮
Research Site, Helsinki, Finland
Phase II Trial of Preoperative Therapy With Gefitinib and Chemotherapy in Patients With ERneg Breast Cancer
- Conditions
- First Posted Date
- 2005-10-17
- Last Posted Date
- 2011-01-27
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 160
- Registration Number
- NCT00239343
- Locations
- 🇸🇪
Research Site, Lund, Sweden
🇩🇰Research Stie, Herlev, Denmark
Gefitinib (Iressa) in Combo With Chemoradiation in Patients With Locally Advanced Head & Neck Cancer
- Conditions
- First Posted Date
- 2005-10-17
- Last Posted Date
- 2007-12-18
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 40
- Registration Number
- NCT00239304
- Locations
- 🇫🇮
Research Centre, Helsinki, Finland
A Phase II Exploratory, Multicentre, Open-label, Non-comparative Study of ZD1839 (Iressa) and Radiotherapy in the Treatment of Patients With Glioblastoma Multiforme
- Conditions
- First Posted Date
- 2005-10-14
- Last Posted Date
- 2011-01-21
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 36
- Registration Number
- NCT00238797
- Locations
- 🇸🇪
Research Site, Umeå, Sweden
Radiation Therapy Combined With Either Gefitinib or Temozolomide in Pats With NSCLC and Brain Metastases
- Conditions
- Interventions
- First Posted Date
- 2005-10-13
- Last Posted Date
- 2012-06-05
- Lead Sponsor
- Swiss Group for Clinical Cancer Research
- Target Recruit Count
- 59
- Registration Number
- NCT00238251
- Locations
- 🇨🇭
Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
🇨🇭Oncology Institute of Southern Switzerland, Bellinzona, Switzerland
🇨🇭Kantonsspital Graubuenden, Chur, Switzerland
IRESSA Combined With Radiotherapy & Gemcitabine as First-Line Treatment in Locally Advanced Pancreatic Cancer
- Conditions
- First Posted Date
- 2005-10-07
- Last Posted Date
- 2009-04-23
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 45
- Registration Number
- NCT00234416
- Locations
- 🇪🇸
Research Site, Valencia, Spain
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.